- Home
- JAZZ vs ABVX Comparison
JAZZ vs ABVX Comparison
Compare JAZZ & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAZZ
- ABVX
- Stock Information
- Founded
- JAZZ 2003
- ABVX 2013
- Country
- JAZZ Ireland
- ABVX France
- Employees
- JAZZ N/A
- ABVX 69
- Industry
- JAZZ Biotechnology: Pharmaceutical Preparations
- ABVX
- Sector
- JAZZ Health Care
- ABVX
- Exchange
- JAZZ Nasdaq
- ABVX Nasdaq
- Market Cap
- JAZZ 7.9B
- ABVX 6.7B
- IPO Year
- JAZZ 2007
- ABVX N/A
- Fundamental
- Price
- JAZZ $136.58
- ABVX $86.72
- Analyst Decision
- JAZZ Strong Buy
- ABVX Strong Buy
- Analyst Count
- JAZZ 14
- ABVX 9
- Target Price
- JAZZ $179.21
- ABVX $94.11
- AVG Volume (30 Days)
- JAZZ 758.5K
- ABVX 969.2K
- Earning Date
- JAZZ 11-05-2025
- ABVX 08-11-2025
- Dividend Yield
- JAZZ N/A
- ABVX N/A
- EPS Growth
- JAZZ N/A
- ABVX N/A
- EPS
- JAZZ N/A
- ABVX N/A
- Revenue
- JAZZ $4,086,695,000.00
- ABVX $7,073,400.00
- Revenue This Year
- JAZZ $5.70
- ABVX $4.44
- Revenue Next Year
- JAZZ $6.16
- ABVX N/A
- P/E Ratio
- JAZZ N/A
- ABVX N/A
- Revenue Growth
- JAZZ 4.52
- ABVX N/A
- 52 Week Low
- JAZZ $95.49
- ABVX $4.77
- 52 Week High
- JAZZ $148.06
- ABVX $92.91
- Technical
- Relative Strength Index (RSI)
- JAZZ 63.56
- ABVX 68.69
- Support Level
- JAZZ $125.79
- ABVX $81.90
- Resistance Level
- JAZZ $140.39
- ABVX $90.70
- Average True Range (ATR)
- JAZZ 3.18
- ABVX 2.75
- MACD
- JAZZ 0.46
- ABVX -0.69
- Stochastic Oscillator
- JAZZ 71.59
- ABVX 61.24
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.